Trial Profile
Cardiometabolic Risk reduction by rimonabant: the effectiveness in daily practice and its use.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Hyperglycaemia; Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CARDIO-REDUSE
- 13 Dec 2023 Status changed from recruiting to completed.
- 04 Jan 2007 New trial record.